Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 2824/7 Wall Street • 10/25/26
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketZacks Investment Research • 10/23/26
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 10/22/26
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026PRNewsWire • 10/21/26
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks Investment Research • 10/20/26
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsThe Motley Fool • 10/20/26
Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2The Motley Fool • 10/20/26
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.The Motley Fool • 10/18/26
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?Zacks Investment Research • 10/14/26
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with ObesityPRNewsWire • 10/14/26
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?Zacks Investment Research • 10/12/26
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.The Motley Fool • 10/12/26
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?The Motley Fool • 10/10/26
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderZacks Investment Research • 10/09/26
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should KnowZacks Investment Research • 10/08/26
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with ObesityPRNewsWire • 10/06/26
LLY Highlights New Efficacy Data From Foundayo and EloraTZP StudiesZacks Investment Research • 10/02/26
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?The Motley Fool • 10/02/26
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 10/01/26